| 課程內容 |
- 課程主題：三合一氣喘吸入劑
- 課程講師：林慶雄 講師
- 錄製日期：2024.5.5
- 操作方式：點選本頁報名，繳費後至線上課程觀看
- 學分認定：觀看完整影片後(須完成進度100%)即認學分
- 其他說明：聲音較小，請自行調整放大音量
- 課程講義：報名後至附件下載
- 摘要：Triple inhaler therapy, which includes the combination of inhaled corticosteroids (ICS), long-acting β2-agonists (LABA), and long-acting muscarinic antagonists (LAMA), has shown promising results in the treatment of uncontrolled asthma. Studies have demonstrated that triple therapy, whether delivered through a single inhaler or separate inhalers, can lead to a reduction in asthma symptoms, exacerbations, and hospitalizations. Additionally, triple therapy has been associated with improvements in lung function, asthma control, and health-related quality of life. In real-world settings, extrafine single-inhaler triple therapy (efSITT) has shown clinical benefits in patients with asthma not adequately controlled on LABA and medium- or high-dose ICS. Furthermore, first-line triple therapy has been found to be effective in managing controller-naïve and symptomatic adult patients with asthma, leading to improved disease control. Overall, triple inhaler therapy appears to be a valuable treatment option for patients with uncontrolled asthma, offering improved outcomes and potentially reducing the need for dose escalation or alternative treatments.
|